

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising P. falciparum erythrocyte binding protein-2 (EBP2) Region II (RII), the amino acid sequence of which is amino acids 147 to 762 of SEQ ID NO:1 ~~a paralogue of EBA-175 polypeptide sequence.~~

2. (Currently amended) The pharmaceutical composition of Claim 1, wherein the polypeptide comprises P. falciparum erythrocyte binding protein-2 (EBP2), the amino acid sequence of which is ~~paralogue of EBA-175 polypeptide sequence is encoded by the sequence of~~ SEQ ID NO:1.

3. (Original) The pharmaceutical composition of Claim 1, further comprising an isolated sialic acid binding protein (SABP) binding domain polypeptide in an amount sufficient to induce a protective immune response to *Plasmodium falciparum* merozoites in a mammal.

4. (Currently amended) An isolated polypeptide comprising P. falciparum erythrocyte binding protein-2 (EBP2) Region II (RII), the amino acid sequence of which is amino acids 147 to 762 of SEQ ID NO:1 ~~a paralogue of EBA-175 polypeptide sequence.~~

5. (Currently amended) The isolated polypeptide of Claim 4, wherein the polypeptide comprises P. falciparum erythrocyte binding protein-2 (EBP2), the amino acid sequence of which is ~~paralogue of EBA-175 polypeptide sequence is encoded by the sequence of~~ SEQ ID NO:1.

6. (Withdrawn) An isolated nucleic acid sequence comprising a paralogue of EBA-175 nucleic acid sequence.

7. (Withdrawn) The isolated nucleic acid sequence of Claim 6, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

8. (Withdrawn) A vector comprising a paralogue of EBA-175 nucleic acid sequence.

9. (Withdrawn) The vector of Claim 8, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

10. (Withdrawn) A recombinant host cell comprising a paralogue of EBA-175 nucleic acid sequence.

11. (Withdrawn) The recombinant host cell of Claim 10, wherein the paralogue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

Appl. No. : 10/630,629  
Filed : July 29, 2003

12. (Withdrawn) A recombinant host cell comprising the vector of Claim 8.
13. (Withdrawn and Currently amended) A method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 1 a ~~pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a paralogue of EBA-175 polypeptide sequence.~~
14. (Withdrawn and Currently amended) A The method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 2 of Claim 13, wherein the paralogue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
15. (Withdrawn and Currently amended) A The method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 3 of claim 14, further comprising administration to the patient of an immunologically effective amount of an isolated SABP binding domain polypeptide.
16. (Withdrawn) A recombinant method for making a paralogue of EBA-175 polypeptide, comprising:
  - expressing the vector of claim 8 in a host cell; and
  - isolating the paralogue of EBA-175 polypeptide from said host cell.
17. (Withdrawn) An isolated antibody, wherein the antibody binds a 5' cysteine rich region of an EBA-175 protein paralogue from a *Plasmodium* species.
18. (Withdrawn) The isolated antibody of Claim 17, wherein the 5' cysteine rich region is a region II.
19. (Withdrawn) The isolated antibody of Claim 18, wherein the 5' cysteine rich region is a region II/F2.
20. (Withdrawn) The isolated antibody of Claim 17, wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.